Patients will be treated with a mild caloric restriction (15-20% caloric restriction)

Patients will be treated with a mild caloric restriction (15-20% caloric restriction) with exclusion of cow's milk, its derivatives and gluten

Multiple Sclerosis, Relapsing-Remitting

Caloric Restriction

Patients will be treated with a diet regimen of mild caloric restriction (15-20% caloric restriction)

Caloric restriction

Patients will be treated with mild caloric restriction (15-20% caloric restriction) plus excluding from diet cow's milk, its derivatives and gluten.

Caloric restriction without cow's milk and gluten

Italian MS Foundation official site with reference of the Calorie-MS study

Calorie Restriction in Multiple Sclerosis

Calorie Restriction as a Novel Therapeutic Tool to Manipulate Immunity and Improve Therapeutic Potential of First Line Drug Treatments During Relapsing Remitting Multiple Sclerosis

Evaluation of the "no evident disease activity" (NEDA) defined thanks to the evaluation of three components: (i) absence of confirmed disability progression (CDP), (ii) absence of relapses and (iii) absence of radiological activity before and after starting caloric restricted diet.

Evaluation of the percentage of different subclasses of circulating immune cells in the blood of patients

Evaluation of the amount of conventional T cell divisions in the presence or absence of regulatory T cells through evaluation of 3H-thymidine incorporation into new strands of chromosomal DNA

Evaluation of Glycolysis (mpH/min) through measurement of Extracellular Acidification Rate (ECAR) of circulating T cell populations

Evaluation of oxidative phosphorylation (pMol/min) through measurement of Oxygen Consumption Rate (OCR) of circulating T cell populations

Evaluation of the serum/plasma concentration (pg/ml) of circulating adipokines (Leptin, adiponectin, etc...)

Analysis of molecules involved in the signalling pathway after T-cell receptor (TCR) stimulation (ERK-mTOR-p27kip1 etc);

Evaluation of the components of the gut microbiota before and after starting caloric restricted diet.

Giuseppe Matarese

Professor, Principal investigator

Federico II University

Fondazione Italiana Sclerosi Multipla

Sodium propionate will be administered with a daily intake of 2 x 500 mg in form of capsules for 12 weeks.

Endstage Renal Disease

Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.

Sodium Propionate

Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis

Effects of Short-chain Fatty Acids, Here Sodium Propionate, a Metabolism Product of the Human Gut-microbiome, on Inflammatory and Metabolic Parameters in Patients on Maintenance Hemodialysis - a Pilot Study

endotoxin /lipopolysaccharide levels, high sensitivity C-reactive protein (hs-CRP), fibrinogen, interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), IL-10, IL-2, INFγ, TGFβ, IL-4, IL-1β, IL-17a and white blood cell count.

glutathione peroxidase, malone dialdehyde

Determination of Homa Index (Homeostasis Model Assessment) by measurement fasting blood sugar and insulin level as well as hemoglobin HbA1c. IR appears to be as associated of metabolic disorders including lipid abnormalities, atherosclerotic cardiovascular disease and accelerated muscle protein degradation (Wang et al. 2006). IL is induced in particular by systemic inflammation.

encephalomyelitis/ожиріння

Calorie Restriction in Multiple Sclerosis

Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis

Найповніша база даних про лікарські трави, підкріплена наукою